Madrid, Spain: Spanish regulators have approved the sale and marketing of Sativex, an oral spray consisting of natural cannabis extracts (primarily the plant cannabinoids THC and cannabidiol aka CBD) as an adjunct therapy for the treatment of multiple sclerosis. (MS).
The approval comes some two months after British health regulators legalized the drug. Separate regulatory approval remains pending in several additional European markets, including France, Germany, and Italy.
Sativex was approved in Canada in 2005.
In clinical trials, Sativex has been demonstrated to reduce MS-associated spasticity, pain, and incontinence. Long-term investigational trials indicate that consistent use of the cannabis-based medicine may also slow the progression of the disease.
Clinical trials to assess the use of Sativex to treat cancer pain are pending in the United States.
For more information, please visit: http://www.gwpharm.com.